A61P 27/16
Otologicals
A61P27/16 (Otologicals) appears on 3,960 US grants and 5,972 published applications in this corpus.
Search patents in A61P- Granted patents
- 3,960
- Published applications
- 5,972
- Assignees
- 1,874
- Inventors
- 10,443
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 2 | 0 |
| 1979 | 3 | 0 |
| 1980 | 1 | 0 |
| 1981 | 4 | 0 |
| 1982 | 4 | 0 |
| 1983 | 2 | 0 |
| 1984 | 2 | 0 |
| 1985 | 3 | 0 |
| 1986 | 4 | 0 |
| 1987 | 7 | 0 |
| 1988 | 10 | 0 |
| 1989 | 16 | 0 |
| 1990 | 12 | 0 |
| 1991 | 9 | 0 |
| 1992 | 9 | 0 |
| 1993 | 5 | 0 |
| 1994 | 13 | 0 |
| 1995 | 17 | 0 |
| 1996 | 28 | 0 |
| 1997 | 29 | 0 |
| 1998 | 43 | 0 |
| 1999 | 75 | 0 |
| 2000 | 58 | 0 |
| 2001 | 108 | 19 |
| 2002 | 93 | 126 |
| 2003 | 77 | 227 |
| 2004 | 91 | 319 |
| 2005 | 104 | 326 |
| 2006 | 120 | 297 |
| 2007 | 156 | 341 |
| 2008 | 148 | 360 |
| 2009 | 153 | 451 |
| 2010 | 225 | 446 |
| 2011 | 225 | 395 |
| 2012 | 258 | 328 |
| 2013 | 243 | 240 |
| 2014 | 233 | 254 |
| 2015 | 203 | 222 |
| 2016 | 165 | 239 |
| 2017 | 163 | 218 |
| 2018 | 138 | 194 |
| 2019 | 154 | 182 |
| 2020 | 145 | 160 |
| 2021 | 100 | 120 |
| 2022 | 84 | 132 |
| 2023 | 57 | 100 |
| 2024 | 70 | 113 |
| 2025 | 61 | 104 |
| 2026 | 28 | 59 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Complex composition for preventing or treating hearing loss including sarpogrelate and Vaccinium myrtillus extract as active ingredients15 Sep 2026US 12,734,205 B2Imdpharm Inc.
- Compositions and methods to treat or prevent metabolic fatigue using the compound oleuropein or a metabolite thereof18 Aug 2026US 12,708,639 B2Societe des Produits Nestle S. A.
- Calcineurin inhibitors of the setron family for the treatment of hearing loss11 Aug 2026US 12,702,671 B2Sensorion
- Tetrahydroisoquinoline compound as potassium channel modulator and preparation and application thereof11 Aug 2026US 12,703,687 B2Shanghai Zhimeng Biopharma, Inc.
- Methods of treating hearing loss using a secreted target protein11 Aug 2026US 12,703,874 B2Akouos, Inc.
- Intranasal administration of ngf for the treatment of sensorineural hearing loss8 Oct 2026US 2026/0308216 A1Dompé Farmaceutici S.P.A.
- Compositions and methods for treating gjb2-related hearing loss8 Oct 2026US 2026/0308625 A1Decibel Therapeutics, Inc.
- Composition for treating ototoxic hearing loss caused by aminoglycoside antibiotics1 Oct 2026US 2026/0294880 A1Industry-Academic Coorperation Foundation Daegu Haany University
- Corticosteroid nanosuspensions and uses thereof1 Oct 2026US 2026/0294934 A1Aimmax Therapeutics, Inc.
- Substituted pyrimidinone and azapyrimidinone compounds, compositions, and uses thereof1 Oct 2026US 2026/0297118 A1
Most cited
By later US patents
- Albumin fusion proteins comprising GLP-1 polypeptides198US 7,141,547 B2Human Genome Sciences, Inc. · 2006
- Bi-aryl meta-pyrimidine inhibitors of kinases194US 7,528,143 B2TargeGen, Inc. · 2009
- Intermediates useful for making 2,4-pyrimidinediamine compounds192US 7,060,827 B2Rigel Pharmaceuticals, Inc. · 2006
- Urea substituted imidazoquinolines182US 6,541,485 B13M Innovative Properties Company · 2003
- Urea substituted imidazoquinolines181US 6,573,273 B13M Innovative Properties Company · 2003